Tag Archive for: STC-15

STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications

/in

8 January 2026, Cambridge, UK, and San Diego, US: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida Biosciences Inc. (AlidaBio), a company at the forefront of epitranscriptomics and RNA modification analysis. STORM will utilize AlidaBio’s advanced EpiPlex® and EpiScout® next-generation sequencing […]

Read more

STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer

/in

STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor Collaboration enables Phase 1b/2 study with STORM’s lead product, STC-15 in combination with Coherus’s next generation PD-1 inhibitor, LOQTORZI® (toripalimab) in patients with NSCLC, HNSCC, melanoma, and endometrial cancer Atif Abbas, M.D. joins as Chief Medical Officer 27 […]

Read more

STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024

/in

STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types Gene expression data shows upregulation of innate immunity pathways Tumor regressions observed at all dose levels, 60-200 mg TIW 11 November 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat […]

Read more

STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium

/in

STC-15 is the first METTL3 inhibitor to enter clinical development Presentation to highlight updated interim results, demonstrating that STC-15 was well tolerated, and clinical activity observed across pharmacologically active dose range in advanced cancer patients 9 October 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat […]

Read more

Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery

/in

Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled novel targets to treat diseases 17 June 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, is delighted to announce that its Founder & Director and Professor of Cancer Biology, University of Cambridge, UK, Tony Kouzarides, […]

Read more